Abemaciclib
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sarcoma
Conditions
Sarcoma, Dedifferentiated Liposarcoma
Trial Timeline
Jul 1, 2016 → Jul 1, 2026
NCT ID
NCT02846987About Abemaciclib
Abemaciclib is a phase 2 stage product being developed by Eli Lilly for Sarcoma. The current trial status is active. This product is registered under clinical trial identifier NCT02846987. Target conditions include Sarcoma, Dedifferentiated Liposarcoma.
What happened to similar drugs?
1 of 15 similar drugs in Sarcoma were approved
Approved (1) Terminated (1) Active (13)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02792725 | Pre-clinical | Completed |
| NCT03763604 | Pre-clinical | Completed |
| NCT06025747 | Phase 1 | Recruiting |
| NCT06678269 | Phase 1 | Recruiting |
| NCT04003896 | Phase 2 | Terminated |
| NCT04408924 | Phase 2 | Completed |
| NCT04681768 | Pre-clinical | Completed |
| NCT03891784 | Phase 2 | Active |
| NCT03837821 | Phase 1 | Active |
| NCT03339843 | Phase 2 | Completed |
| NCT03703466 | Phase 2 | Completed |
| NCT03310879 | Phase 2 | Recruiting |
| NCT02919696 | Phase 1 | Completed |
| NCT03130439 | Phase 2 | Terminated |
| NCT02981940 | Phase 2 | Active |
| NCT02846987 | Phase 2 | Active |
| NCT02482935 | Phase 1 | Completed |
| NCT02308020 | Phase 2 | Completed |
| NCT02387814 | Phase 1 | Completed |
| NCT02102490 | Phase 2 | Completed |
Competing Products
20 competing products in Sarcoma